Abstract
The roles of ghrelin, a peptide hormone that has a role in regulating food intake and energy homeostasis, in the cardiovascular system have not yet been unambiguously established. We evaluated the association between plasma ghrelin concentrations and −501A>C single-nucleotide polymorphism (SNP) in the ghrelin gene 5′ flanking area and echocardiographic measurements in 1037 middle-aged subjects. Left ventricular mass index (LVMI) was calculated according to Devereux's method. The ambulatory blood pressure (BP) was recorded using the fully automatic SpaceLabs 90207 oscillometric unit. Results suggested that plasma ghrelin was not related to mean ambulatory BP values. However, the highest plasma ghrelin tertile was associated with increased intraventricular septum (P=0.043) and posterior ventricular wall (P=0.002) thicknesses as well as left ventricular mass (P=0.05). After adjustment for age, sex, body mass index and systolic BP, the association persisted between ghrelin tertiles and intraventricular septum (P=0.05) and posterior ventricular wall (P=0.001) thicknesses. The SNP −501A>C polymorphism was associated with LVMI after adjustments for age, sex and systolic BP. In conclusion, ghrelin and its promoter variant are associated with cardiac hypertrophy indexes independent of BP. Positive correlation between ghrelin levels and increased wall thickness parameters may reflect compensatory up-regulation of ghrelin concentrations or direct effects of ghrelin on myocardium. The effects of the SNP seem not to be mediated through its effects on ghrelin plasma levels.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K . Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999; 402: 656–660.
Kojima M, Kangawa K . Ghrelin: structure and function. Physiol Rev 2005; 85: 495–522.
Iglesias MJ, Piñeiro R, Blanco M, Gallego R, Diéguez C, Gualillo O et al. Growth hormone releasing peptide (ghrelin) is synthesized and secreted by cardiomyocytes. Cardiovasc Res 2004; 62: 481–488.
Nagaya N, Kojima M, Uematsu M, Yamagishi M, Hosoda H, Oya H et al. Hemodynamic and hormonal effects of human ghrelin in healthy volunteers. Am J Physiol Regul Integr Comp Physiol 2001; 280: R1483–R1487.
Li L, Zhang L, Pang Y, Pan C, Qi Y, Chen L et al. Cardioprotective effects of ghrelin and des-octanoyl ghrelin on myocardial injury induced by isoproterenol in rats. Acta Pharmacol Sin 2006; 27: 527–535.
Matsumura K, Tsuchihashi T, Fujii K, Abe I, Iida M . Central ghrelin modulates sympathetic activity in conscious rabbits. Hypertension 2002; 40: 694–699.
Nagaya N, Moriya J, Yasumura Y, Uematsu M, Ono F, Shimizu W et al. Effects of ghrelin administration on left ventricular function, exercise capacity, and muscle wasting in patients with chronic heart failure. Circulation 2004; 110: 3674–3679.
Vestergaard ET, Andersen NH, Hansen TK, Rasmussen LM, Moller N, Sorensen KE et al. Cardiovascular effects of intravenous ghrelin infusion in healthy young men. Am J Physiol Heart Circ Physiol 2007; 293: H3020–H3026.
Tesauro M, Schinzari F, Caramanti M, Lauro R, Cardillo C . Metabolic and cardiovascular effects of ghrelin. Int J Pept 2010 Epub 16 Mar 2010.
Tritos NA, Kissinger KV, Manning WJ, Danias PG . Association between ghrelin and cardiovascular indexes in healthy obese and lean men. Clin Endocrinol (Oxf) 2004; 60: 60–66.
Rodríguez A, Gómez-Ambrosi J, Catalán V, Becerril S, Sáinz N, Gil MJ et al. Association of plasma acylated ghrelin with blood pressure and left ventricular mass in patients with metabolic syndrome. J Hypertens 2010; 28: 560–567.
Baessler A, Kwitek AE, Fischer M, Koehler M, Reinhard W, Erdmann J et al. Association of the Ghrelin receptor gene region with left ventricular hypertrophy in the general population: results of the MONICA/KORA Augsburg Echocardiographic Substudy. Hypertension 2006; 47: 920–927.
Rantala AO, Kauma H, Lilja M, Savolainen MJ, Reunanen A, Kesäniemi YA . Prevalence of the metabolic syndrome in drug-treated hypertensive patients and control subjects. J Intern Med 1999; 245: 163–174.
Du Bois D, Du Bois EF . A formula to estimate the approximate surface area if height and weight be known. Arch Intern Med 1916; 17: 863–871.
Vasunta RL, Kesäniemi YA, Ukkola O . Plasma adiponectin concentration is associated with ambulatory daytime systolic blood pressure but not with the dipping status. J Hum Hypertens 2010; 24: 545–551.
Pöykkö SM, Kellokoski E, Horkko S, Kauma H, Kesaniemi YA, Ukkola O . Low plasma ghrelin is associated with insulin resistance, hypertension, and the prevalence of type 2 diabetes. Diabetes 2003; 52: 2546–2553.
Vartiainen J, Kesaniemi YA, Ukkola O . Sequencing analysis of ghrelin gene 5′ flanking region: relations between the sequence variants, fasting plasma total ghrelin concentrations, and body mass index. Metabolism 2006; 55: 1420–1425.
Sahn DJ, DeMaria A, Kisslo J, Weyman A . The committee on M-mode standardization of the American Society of Echocardiography: recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 1978; 58: 1072–1083.
Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Gampo E, Sachs I et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986; 57: 450–458.
Arvat E, Di Vito L, Broglio F, Papotti M, Muccioli G, Dieguez C et al. Preliminary evidence that Ghrelin, the natural GH secretagogue (GHS)-receptor ligand, strongly stimulates GH secretion in humans. J Endocrinol Invest 2000; 23: 493–495.
Colao A, Marzullo P, Di Somma C, Lombardi G . Growth hormone and the heart. Clin Endocrinol (Oxf) 2001; 54: 137–154.
Shimizu Y, Nagaya N, Teranishi Y, Imazu M, Yamamoto H, Shokawa T et al. Ghrelin improves endothelial dysfunction through growth hormone-independent mechanisms in rats. Biochem Biophys Res Commun 2003; 310: 830–835.
Baldanzi G, Filigheddu N, Cutrupi S, Catapano F, Bonissoni S, Fubini A et al. Ghrelin and des-acyl ghrelin inhibit cell death in cardiomyocytes and endothelial cells through ERK1/2 and PI 3-kinase/AKT. J Cell Biol 2002; 159: 1029–1037.
Pöykkö SM, Kellokoski E, Ukkola O, Kauma H, Paivansalo M, Kesaniemi YA et al. Plasma ghrelin concentrations are positively associated with carotid artery atherosclerosis in males. J Intern Med 2006; 260: 43–52.
Berthold HK, Giannakidou E, Krone W, Trégouët DA, Gouni-Berthold I . Influence of ghrelin gene polymorphisms on hypertension and atherosclerotic disease. Hypertens Res 2010; 33: 155–160.
Garcia EA, King P, Sidhu K, Ohgusu H, Walley A, Lecoeur C et al. The role of ghrelin and ghrelin-receptor gene variants and promoter activity in type 2 diabetes. Eur J Endocrinol 2009; 161: 307–315.
Acknowledgements
This study was supported by the Medical Council of the Academy of Finland and the Finnish Foundation for Cardiovascular Research. We thank Markku Ikäheimo MD, PhD for the expert ultrasound examinations. We acknowledge the excellent technical assistance of, Ms Helena Kalliokoski, Ms Saija Kortetjärvi, Ms Sirpa Rannikko and Ms Liisa Mannermaa.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Ukkola, O., Pääkkö, T. & Kesäniemi, Y. Ghrelin and its promoter variant associated with cardiac hypertrophy. J Hum Hypertens 26, 452–457 (2012). https://doi.org/10.1038/jhh.2011.51
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/jhh.2011.51